Cue Biopharma, Inc. is a clinical-stage biopharmaceutical enterprise focused on creating biological therapies. Its central objective is the precise manipulation of the ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-1.34 · Revenue $1.55M · 2 analysts
Est. EPS $-1.22 · Revenue $1.50M · 2 analysts
Est. EPS $-21.45 · Revenue $16.63M · 1 analysts
Est. EPS $-6.83 · Revenue $10.28M · 2 analysts
EPS $-2.66 · Revenue $2.95M
EPS $-5.10 · Revenue $421000.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $27.5M | +195.7% | +38.5% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-26.6M | +34.6% | -2856.1% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +100.0% | 0.0% | -0.5% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -96.6% | +78.4% | -1080.4% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -96.9% | +77.9% | -2033.9% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-21.9M | +39.9% | -162.2% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -79.6% | +79.7% | -89.2% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 15.9% | -68.7% | +2294.8% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 2.74x | +49.2% | -64.9% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $42.2M | +31.1% | -0.6% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -8.40 vs -12.00 | +30.0% | -24.14 vs -1.69 | -1328.4% |
| Revenue Surprise | $27.5M vs $6.5M | +322.6% | $7.9M vs $3.0M | +162.6% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Ray Sumita | officer, other: Chief Legal Compliance Officer | Common Stock | A | 18,196 | — |
| Aug 13, 2026 | Ray Sumita | officer, other: Chief Legal Compliance Officer | Common Stock | D | 2,383 | $29.37 |
| Aug 13, 2026 | Ray Sumita | officer, other: Chief Legal Compliance Officer | Common Stock | D | 6,442 | $30.35 |
| Aug 13, 2026 | Ray Sumita | officer, other: Chief Legal Compliance Officer | Common Stock | D | 4 | $31.13 |
| Aug 13, 2026 | Ray Sumita | officer, other: Chief Legal Compliance Officer | Common Stock | D | 18,196 | — |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
James Ahlers | Chief Financial Officer | USD 577,276 | Male | 1964 | Active |
Lucinda Warren | Principal Accounting Officer & Chief Business Officer | USD 470,948 | Female | 1969 | Active |
Colin G. Sandercock | Senior Vice President of Intellectual Property | USD 449,642 | Male | 1957 | Active |
Shao-Lee Lin | President, CEO & Director | USD 434,202 | — | 1967 | Active |
Rodolfo J. Chaparro | Co-Founder | USD 316,628 | — | 1973 | Active |
Ronald D. Seidel | Co-Founder | USD 316,628 | — | 1976 | Active |
Agnes Lee | Chief Officer of Public & Investor Relations | — | Female | — | Active |
Sumita Ray | Chief Legal & Compliance Officer and Corporate Secretary | — | Female | 1974 | Active |
Steven C. Almo | Co-Founder and Chairman of Scientific & Clinical Advisory Board | — | — | 1961 | Active |
Daniel G. Baker | Interim Chief Development Officer | — | — | 1950 | Active |
NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Cue Biopharma, Inc. (NASDAQ: CUE) on behalf of the company's shareholders. The investigation seeks to determine whether Cue Biopharma's directors breached their fiduciary duties in connection with recent corporate actions.
BOSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today reported second quarter 2026 financial results as well as recent business highlights.
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company targeting transformative therapies for immune-mediated diseases, today announced the appointment of James M. Ahlers as Chief Financial Officer.
Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases
BOSTON, July 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical stage biopharmaceutical company focused on developing transformative therapies targeting functional cures for immunological disorders, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of (i) 1,418,071 shares of common stock at a purchase price of $33.21 per share and (ii) to certain investors, in lieu of shares of common stock, pre-funded warrants to purchase up to 87,500 shares of common stock at a price per pre-funded warrant of $33.209, for gross proceeds of approximately $50.0 million.
